# P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

> **NCT00603642** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 34 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Placebo
- **DRUG:** AMG 531

## Key facts

- **NCT ID:** NCT00603642
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-01
- **Primary completion:** 2009-04-13
- **Final completion:** 2009-04-13
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603642, "P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00603642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*